The TAK-935 clinical trial was focused on the conditions of epilepsy, Dravet syndrome, Lennox–Gastaut syndrome, 15q duplication syndrome, CDKL5 deficiency disease, and developmental and/or epileptic encephalopathies. Here, CDKL5 is linked to Dravet syndrome.